ストックスクリーナーアプリを入手
25.39
2.21%
0.55
アフターアワーズ：
25.35
-0.04
-0.16%
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
4 Medical Stocks With the Right Setup for Q2 Earnings Beats - TradingView
Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout (NASDAQ:ACAD) - Seeking Alpha
ACADIA Pharmaceuticals Inc (ACAD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ACAD|ACADIA Pharmaceuticals Inc|Price:24.840|Chg%:+0.010 - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Cash Flow - TradingKey
Stifel Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Raises Target Price to $25 - Moomoo
ACAD: Acadia Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
ACADIA Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc (ACAD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Mizuho Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Acadia gains fast track status for remlifanserin in Alzheimer's disease psychosis - MSN
Mizuho Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate - TradingView
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Exploring a 30% Potential Upside Amid Robust Growth - DirectorsTalk Interviews
Mizuho reiterates Acadia stock rating on Alzheimer’s trial progress - Investing.com UK
Stifel raises Acadia Pharmaceuticals price target on drug potential By Investing.com - Investing.com South Africa
Stifel raises Acadia Pharmaceuticals price target on drug potential - Investing.com
Acadia Pharmaceuticals (ACAD) Receives FDA Fast Track for Remlif - GuruFocus
Lobbying Update: $700,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis - BioSpace
ETFs Investing in ACADIA Pharmaceuticals Inc. Stocks - TradingView
JP Morgan Maintains ACADIA Pharmaceuticals (ACAD) Overweight Recommendation - MSN
ACADIA Pharmaceuticals (ACAD) Stock Trades At A Discount To Earnings But Faces Concentrated Risk - webull.com
ACADIA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GAROFALO ELIZABETH A.moomoo - Moomoo
Understanding the Setup: (ACAD) and Scalable Risk - Stock Traders Daily
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 - BioSpace
Bank of America Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Press Release: Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 - Moomoo
Acadia Pharmaceuticals to announce Q2 2026 results on August 4 - scanx.trade
Acadia to Host Q2 Results Call After Markets Close Aug. 4 - Stock Titan
BofA Securities Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $30 - Moomoo
ACADIA Pharmaceuticals Inc (ACAD) Institutional Confidence - TradingKey
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? - The Motley Fool
Acadia rises as EU backs Rett syndrome therapy - MSN
ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value? - Yahoo Finance
Why Acadia Pharmaceuticals stock is soaring today - MSN
ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run - Sahm
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win? - Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Undervalued On Rett Progress And Its Leadership Change? - simplywall.st
How CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors - Yahoo Finance
H.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Carl Segerstrom Appointed Chief People Officer at Acadia Pharmaceuticals - hrtoday.in
Should EMA’s Positive Rett Syndrome Opinion for DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative? - Sahm
RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating - Moomoo
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $36 - Moomoo
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):